title: Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
authors.forename: Hussam
authors.initials: H
authors.lastname: Ghoti
authors.forename: Eitan
authors.initials: E
authors.lastname: Fibach
authors.forename: Drorit
authors.initials: D
authors.lastname: Merkel
authors.forename: Galit
authors.initials: G
authors.lastname: Perez-Avraham
authors.forename: Sigal
authors.initials: S
authors.lastname: Grisariu
authors.forename: Eliezer A
authors.initials: EA
authors.lastname: Rachmilewitz
mesh_terms: D000284:Administration, Oral; D000368:Aged; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D000077588:Deferasirox; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron / Q000097:blood; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019190:Iron Overload / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy*; D018384:Oxidative Stress / Q000187:drug effects*; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001565:Benzoates; D015415:Biomarkers; D007502:Iron Chelating Agents; D014230:Triazoles; D005293:Ferritins; D007501:Iron; D000077588:Deferasirox